Adiponectin News and Research

RSS

Positive results from DARA's DB959 Phase 1b study on type 2 diabetes

DARA BioSciences, Inc., announces the positive results from a successfully completed Phase 1b clinical study for DB959, its peroxisome proliferator activated receptor (PPAR)-delta/gamma agonist, a non-TZD oral drug in development for the treatment of type 2 diabetes.

2 Nov 2011

Specific metabolic disturbances precede children's progression to Type 1 diabetes

New potential avenues for early disease detection and prevention: A study led by Matej Orešič from VTT Technical Research Centre of Finland suggests that autoimmune diabetes is preceded by diminished gut microbial diversity of the Clostridium leptum subgroup, elevated plasma leptin and enhanced glucose-stimulated insulin secretion.

29 Oct 2011

New biological insights into fat tissue

For better or worse, a popular class of anti-diabetic drugs does more than lower blood sugar. One known as rosiglitazone has been in the spotlight for its possible link to increased cardiovascular events, but it also seems to come with unexplained vascular benefits and an unwelcome tendency for weight gain.

6 Jul 2011

New data from Zafgen's ZGN-433 Phase 1b study on obesity presented at ADA 2011

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced new data from a Phase 1b study of ZGN-433, a selective methionine aminopeptidase 2 inhibitor (MetAP2), which showed a significant improvement in cardiovascular risk markers in severely obese subjects.

27 Jun 2011

Charisela develops breakthrough adiponectin assay

Charisela Technologies, Inc., a manufacturer of advanced assays for flow cytometers, announced today that it has developed an adiponectin assay with major advantages over existing technologies, including the elimination of dilutions. Adiponectin (Acrp30), an adipocytokine, is important in many therapeutic arenas, including type 2 diabetes, obesity, atherosclerosis, and rheumatoid arthritis.

9 May 2011

Walking slows progression of nonalcoholic fatty liver disease in obese people

Walking on a treadmill for one hour a day may slow the progression of nonalcoholic fatty liver disease in obese people with prediabetes by jump-starting their metabolism and slowing the oxidative damage wrought by the condition, say researchers at the Cleveland Clinic.

15 Apr 2011

Daily dose of safflower oil can help reduce cardiovascular disease

A daily dose of safflower oil, a common cooking oil, for 16 weeks can improve such health measures as good cholesterol, blood sugar, insulin sensitivity and inflammation in obese postmenopausal women who have Type 2 diabetes, according to new research.

22 Mar 2011

FDA accepts Arisaph's ARI-3037MO IND for phase I human clinical trial

Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted the Company's recently submitted Investigational New Drug application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.

22 Mar 2011

Human growth, height, size: Reasons to be small

Almost everybody these days thinks that it is best to be tall, meaning much taller than the average traditional height of Asian populations, and even taller than the current average height of populations in high-income countries. It is also often believed – though people might be shy to admit this – that tall people are intrinsically superior to short people. The expressions 'look up to' and 'look down on' are significant.

15 Mar 2011

Increased alcohol consumption leads to multiple cardiovascular outcomes

A summary paper on the effects of alcohol consumption on biologic mechanisms associated with coronary heart disease provides an excellent review of a large number of intervention studies in humans.

8 Mar 2011

Women with PCOS face high risk of type 2 diabetes due to aberrations in fat tissue

A study from the University of Gothenburg, shows that women with polycystic ovary syndrome (PCOS) have aberrations in their adipose tissue.

17 Jan 2011

Resveratrol stimulates expression of adiponectin hormone: Study

Resveratrol, a compound in grapes, displays antioxidant and other positive properties. In a study published this week, researchers at the UT Health Science Center San Antonio describe a novel way in which resveratrol exerts these beneficial health effects.

10 Jan 2011

New findings may solve mystery about how starvation hormone affects multiple biological systems

New findings by UT Southwestern Medical Center researchers may solve a 17-year-old mystery about how the so-called "starvation hormone" affects multiple biological systems, including preventing insulin sensitivity and promoting cell survival.

27 Dec 2010

Researchers explain how adiponectin prevents stress-induced damage in heart

One of the many advantages of maintaining a normal body weight is having healthy fat, which in turn supports a healthy heart. Fat tissue is increasingly seen as more than just a storage depot - it's also an active secretory organ that normally produces high levels of a cardioprotective hormone called adiponectin. How adiponectin protects the hearts of healthy people has long been a mystery, and now a team led by Barbara Ranscht, Ph.D. and Pilar Ruiz-Lozano, Ph.D. at Sanford-Burnham Medical Research Institute (Sanford-Burnham) reveals that the protein T-cadherin is the receptor that anchors adiponectin to heart cells.

2 Nov 2010

Protein hormone inhibits leptin-induced migration of liver cancer cells

A research team from Emory University School of Medicine investigated the role between adiponectin and leptin in obesity-related carcinogenesis. Their findings, published in the November issue of Hepatology, suggest that the protein hormone adiponectin has potential for inhibiting the oncogenic actions of leptin, namely in hepatocellular carcinoma (HCC), and could offer a promising therapy for the disease.

19 Oct 2010

Study reveals copy number variants exclusive to obese children

A new study by pediatric researchers has added to the evidence that genes have a strong influence on childhood obesity.

15 Oct 2010

Research finds fat cells can secrete hormones

Scientists are reporting new evidence that the fat tissue in those spare tires and lower belly pooches - far from being a dormant storage depot for surplus calories - is an active organ that sends chemical signals to other parts of the body, perhaps increasing the risk of heart attacks, cancer, and other diseases. They are reporting discovery of 20 new hormones and other substances not previously known to be secreted into the blood by human fat cells and verification that fat secretes dozens of hormones and other chemical messengers.

14 Oct 2010

Acceleron announces ACE-031 Phase 1b study results

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced preliminary results from a Phase 1b study to assess the safety, tolerability and pharmacodynamic (PD) activity of ACE-031 following multiple ascending doses in healthy postmenopausal volunteers.

14 Oct 2010

Low-fat diet reduces risk of heart disease

Losing weight, especially among adults who are very heavy to obese, is a good way to prevent the onset of atherosclerosis, the artery-thickening condition that leads to potentially deadly heart disease. A diet that is low in either fats or carbohydrates can help reduce weight. But which one is the more heart-healthy?

8 Oct 2010

ChemoCentryx presents CCX140 clinical data at EASD

ChemoCentryx, Inc., today announced that it reported positive preclinical and Phase I study results at the European Association for the Study of Diabetes (EASD). CCX140, a novel, orally bioavailable small molecule antagonist of the chemokine receptor CCR2, improved metabolic function while significantly reducing inflammatory macrophages found in adipose tissue in an animal model, and was well tolerated in Phase I clinical trials.

21 Sep 2010